Know Cancer

forgot password

PHASE III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin in Prevention and Reduction of Oxaliplatin-induced Painful Neuropathy

Phase 3
18 Years
Open (Enrolling)
Pain, Neuropathic Pain, Polyneuropathy

Thank you

Trial Information

PHASE III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin in Prevention and Reduction of Oxaliplatin-induced Painful Neuropathy


1.1. Primary Objectives

The primary objective of this study is to evaluate the efficacy of co-administration of
Pregabalin during oxaliplatin infusion in reducing the appearance of both acute and late
onset oxaliplatin-induced painful neuropathy in patients with colorectal cancer.

1.2. Secondary Objectives

The secondary objectives of this study are as follows:

- To compare the pain intensity and interference between the two treatment arms

- To compare the safety profile between the two treatment arms

- To compare quality of life between the two treatment arms

- To compare the percentage of patients with neuropathy between the two treatment groups

- To compare the intensity of neuropathy related to oxaliplatin between the two arms

- To compare the small fiber function and positive sensory signs before and after
treatment with Pregabalin

- To compare mood (depression and anxiety) before and after treatment with Pregabalin in
each treatment arm

- To assess the association between cumulative oxaliplatin dose and time for painful
neuropathy and peripheral sensory neuropathy diagnosis, pain intensity, pain
interference and small fiber function.


2.1 Pregabalin Administration

Treatment will be administered on an outpatient basis. Reported adverse events and
potential risks are described in Section 7. Appropriate dose modifications for Pregabalin
are described in Section 6. No investigational or commercial agents or therapies other than
those described below may be administered with the intent to treat the patient's
oxaliplatin-induced painful neuropathy.

Patients will receive either Pregabalin or placebo three days before and three days
following the OX infusion (week 1, 3, and 5 from each of the three cycles, in a total of
nine sessions).

The total daily dose of Pregabalin will be flexible in the first dose, and then, a fixed
dose will be set for each individual. Before the first Ox dose, patients will start on 75mg
bid and will be followed by telephone contact by a research nurse who will instruct them to
optimize the dose of Pregabalin every two days according to the magnitude and profile of
side effects.

The minimum daily dose to allow for entry in the study is 150mg/day upon the first Ox
infusion. Such a "guided" dose escalation will only be performed before the first Ox
infusion and will last for four days. Thereafter, the maximum tolerated dose used before the
first Ox infusion will be used during the three following days and during the rest of the
study. The same protocol will be performed in the placebo group.

After signing the informed consent and agreeing to participate in the protocol, patients
will undergo the "guided" Pregabalin dose escalation for four days. Then, they will receive
Pregabalin for the three days following the first Ox infusion. Thereafter, they will receive
this same Pregabalin dosage for six days during the eight next Ox infusions sessions ie.,
starting three days before and ending on the third day after each Ox infusion session (from
D-3 to D+3)

2.2 Duration of Therapy

In the absence of treatment delays due to adverse event(s), treatment may continue for 3
cycles of FLOX (totalizing nine oxaliplatin infusions) or until one of the following
criteria applies:

Intercurrent illness that prevents further administration of treatment,

Unacceptable adverse event(s),

Patient decides to withdraw from the study, or

General or specific changes in the patient's condition render the patient unacceptable for
further treatment in the judgment of the investigator.

2.3 FLOX administration

Treatment with fluorouracil plus leucovorin and oxaliplatin (FLOX) 28, 29 will be
administered on an outpatient basis.

Patients will receive intravenous (IV) treatment weekly for 6 weeks of each 8-week cycle for
three cycles. Chemotherapy with FLOX is to be given for 3 cycles in both treatment arms.

FLOX regimen includes:

- Oxaliplatin will be administered at a dose of 85mg/m2 IV on weeks 1, 3, and 5 of each
8-week cycle for three cycles.

- 5-Fluorouracil (5-FU) will be administered at a dose of 500mg/m2 IV bolus weekly for 6
weeks (on weeks 1, 2, 3, 4, 5, and 6).

- Leucovorin 20 mg/m2 IV will be administered on weeks 1, 2, 3, 4, 5, and 6.

Drugs to be administered before chemotherapy:

Dexamethasone 20 mg IV and Ondansetron 8mg IV will be administered before chemotherapy
administration. Dexamethasone will be administered on weeks 1, 3, and 5. Ondansetron will be
administered on weeks 1, 2, 3, 4, 5, and 6.

Drugs to be administered after chemotherapy:

Patients will also receive dexamethasone 4 mg P.O. BID for three days and ondansetron 8 mg
P.O. each 8 hours (if necessary) after each dose of the Oxaliplatin (on weeks 1, 3, and 5).

2.4 Duration of Follow-up

Patients will be followed for 6 months after removal from study or until death, whichever
occurs first. Patients removed from study for unacceptable adverse events will be followed
until resolution or stabilization of the adverse event.

2.5 Criteria for study withdraw

After fulfilling all the inclusion criteria and not presenting any exclusion criteria, and
having started on the protocol, patients will be removed from it if at least one of the
conditions bellow is met:

1. Voluntary consent withdraw by the patients, due to any reason;

2. The patient is considered non compliant to the protocol (ie. more than three absences
in regular protocol visits or failure to take Pregabalin for two treatment session with

In all cases of removal, the patient data and reason for removal will be recorded.

Inclusion Criteria:

- Patient must have histologically or cytologically confirmed colorectal cancer

- Indication of adjuvant chemotherapy regime including oxaliplatin

- Age ≥ 18 years

- Karnofsky performance status (KPS) ≥ 50

- Normal neurological examination

- Be able to understand study protocol

- Ability to understand and the willingness to sign a written informed consent

- The effects of Pregabalin on the developing human fetus at the recommended
therapeutic dose are unknown. For this reason, women of child-bearing and men must
agree to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation. Should
a woman become pregnant or suspect she is pregnant while participating in this study,
she should inform her treating physician immediately.

Exclusion Criteria:

- History of exposure to neurotoxic chemotherapy

- Know Concomitant clinical conditions that impair peripheral nerve function,

- Symptoms or signs suggestive of peripheral neuropathy or neuropathic pain.

- Current peripheral neuropathy of NCI-CTCAE, version 3.0 Grade ≥ 1.

- Inadequate organ function, evidenced by the following laboratory results within 1
week prior to randomization:

- Serum creatinine > 2.0 mg/dL

- Positive blood beta HCG test for women, or women breast feeding

- Assessed by the investigator to be unable or unwilling to comply with the
requirements of the protocol

- History of receiving any investigational treatment within 28 days of randomization

- Patients may not be receiving any other investigational agents.

- Patients with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Pregabalin or known hypersensitivity to the study drug.

- Uncontrolled concurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Outcome Measure:

Evaluate the efficacy

Outcome Description:

Efficacy: the primary endpoint is presence of oxaliplatin-induced painful neuropathy based on Brazilian version of the Douleur Neuropathique 4 Questionnaire (DN4) 1, 2 and intensity of pain based on the numeric pain scale (11-points) of the Brief Pain Inventory.

Outcome Time Frame:

base line and six months after treatment discontinuation

Safety Issue:


Principal Investigator

Daniel C de Andrade, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

ICESP, Departamento de Neurologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo


Brazil: Ethics Committee

Study ID:




Start Date:

August 2011

Completion Date:

December 2013

Related Keywords:

  • Pain
  • Neuropathic Pain
  • Polyneuropathy
  • Neuropathic pain
  • prevention
  • prophylaxis
  • chemotherapy
  • neuropathy
  • Oxaliplatin
  • pregabalin
  • Neuralgia
  • Polyneuropathies